Related references
Note: Only part of the references are listed.Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation
Tomoaki Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
Nozomu Fuse et al.
GASTRIC CANCER (2017)
Hand-Foot Syndrome with Docetaxel: A Five-Case Series
Mirna H. Farhat et al.
ANNALS OF SAUDI MEDICINE (2017)
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older
Koji Kawamura et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies
Hisashi Yamamoto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management
B. McLellan et al.
ANNALS OF ONCOLOGY (2015)
Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
ZhengGang Ren et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management
Kristen K. Miller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia
Johanna Tischer et al.
ANNALS OF HEMATOLOGY (2013)
Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine
Je-Hwan Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
A. Poprach et al.
ANNALS OF ONCOLOGY (2012)
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
Shigeki Ohtake et al.
BLOOD (2011)
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study
Shuichi Miyawaki et al.
BLOOD (2011)
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies
John Magenau et al.
BLOOD (2011)
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
Marcie Tomblyn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Compliance and Effective Manapement of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
Hyun-Sook Son et al.
YONSEI MEDICAL JOURNAL (2009)
Therapeutic drug monitoring of busulfan in transplantation
J. A. Russell et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts
Roger von Moos et al.
EUROPEAN JOURNAL OF CANCER (2008)
VCAP-AMP-VECP compared with biweekly CHOP for adult T-Cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801
Kunihiro Tsukasaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized comparison of four-times-daily versus once-daily intravenous Busulfan in conditioning therapy for hematopoietic cell transplantation
Seong-Gil Ryu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre
Joan D. Webster-Gandy et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule
Timothy Madden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Engraftment syndrome following hematopoietic stem cell transplantation
TR Spitzer
BONE MARROW TRANSPLANTATION (2001)
Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
